GlassScriptPhysician profile
Keenan Rosado
NPI 1356068852
$9,750.84
in general payments reported to CMS, 2019-2025
40 companies · $3,496 in 2025
The $3,496 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $105 · 2023: $2,643 · 2024: $3,507 · 2025: $3,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,645.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,254.46 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $951.12 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $860.61 | 2022-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Novo Nordisk INC | $823.83 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Insulet Corporation | $811.50 | 2023-2025 | Omnipod |
| Amgen INC. | $618.24 | 2023-2025 | Tepezza, Evenity, Prolia |
| Corcept Therapeutics | $593.81 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $443.87 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $264.70 | 2023-2025 | Cequr Simplicity |
| Recordati_rare_diseases_inc. | $253.83 | 2023-2025 | Isturisa, Signifor Lar |
| Astellas Pharma US INC | $229.68 | 2024-2025 | Veozah |
| Tandem Diabetes Care, INC. | $221.11 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $199.08 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $198.00 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Ibsa Pharma INC. | $189.20 | 2022-2025 | Licart, Tirosint, Tirosint |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.10 | 2023-2025 | Synjardy, Jardiance, Tradjenta |
| Alexion Pharmaceuticals, INC. | $146.35 | 2023-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $146.02 | 2023-2025 | Unithroid |
| Radius Health, INC. | $130.40 | 2024-2025 | |
| Horizon Therapeutics Plc | $112.89 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $99.61 | 2023-2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $97.60 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $97.57 | 2024-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $94.41 | 2023-2024 | |
| Antares Pharma, INC. | $86.22 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $82.61 | 2024-2025 | |
| Chiesi USA, INC. | $80.85 | 2025 | Mycapssa |
| Bayer Healthcare Pharmaceuticals INC. | $71.19 | 2023-2025 | |
| Tolmar, INC. | $57.33 | 2023-2025 | Jatenzo |
| Kyowa Kirin, INC. | $50.51 | 2023-2025 | Crysvita |
| Abbott Laboratories | $44.87 | 2025 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $44.35 | 2023-2024 | Crysvita |
| Halozyme INC | $38.14 | 2023 | |
| Esteve Pharmaceuticals LLC | $34.94 | 2025 | Metopirone |
| Esperion Therapeutics, INC. | $33.24 | 2023-2025 | Nexletol |
| Neurocrine Biosciences, INC. | $29.91 | 2025 | |
| Acella Pharmaceuticals, LLC | $28.79 | 2024 | NP Thyroid 60 |
| Arkray USA, INC. | $21.09 | 2023 | |
| Sequel Med Tech, LLC | $20.87 | 2025 | Twiist |
| Renalytix Ai, INC. | $19.94 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keenan Rosado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.